Probe-level performance of Xpert MTB/RIF versus phenotypic culture for rifampicin resistance detection and a triage algorithm based on 3,360 clinical specimens in China.
4 affiliations
- 1Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
- 2Department of Clinical Laboratory, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China. [email protected].
- 3Translational Medicine Center, Guangdong Women and Children Hospital, Guangzhou, Guangdong, China. [email protected].
- 4Fourth People's Hospital of Nanning, Nanning, Guangxi, China. [email protected].
Abstract
Background
The Xpert MTB/RIF (Xpert) assay is a cornerstone for the rapid detection of rifampicin resistance. However, discordant results between Xpert and phenotypic drug susceptibility testing (pDST) present diagnostic challenges, particularly in regions with genetically diverse Mycobacterium tuberculosis populations. This study aimed to evaluate the performance of Xpert at the probe level to resolve such discrepancies and to inform an optimized diagnostic workflow.Methods
Using a retrospective cohort of 3,360 clinical specimens from a high-burden setting in China, we compared Xpert results with pDST as the reference standard. We then performed a stratified analysis based on specific probe mutation patterns to determine their predictive value for phenotypic resistance.Results
Overall, Xpert demonstrated substantial agreement with pDST (κ = 0.722, 95% CI: 0.685-0.759), exhibiting a sensitivity of 80.4% and a specificity of 95.8%. However, concordance was highly dependent on the specific probe mutation. Mutations in Probe E were strongly predictive of phenotypic resistance (Positive Predictive Value: PPV: 91.4%). In contrast, The mutations detected by Probe ΔCt and Probe A exhibited a low PPV of only 28.0% and 14.3%, respectively. Based on these findings, we propose a diagnostic triage strategy: results indicating Probe E mutations can reliably guide immediate treatment adjustments, whereas isolated ProbeΔCt resistance, or Probe A mutations, warrant confirmatory pDST before initiating second-line regimens.Conclusion
The clinical interpretation of Xpert results requires a nuanced understanding of probe-specific mutation patterns. Our probe-stratified analysis and the resulting triage algorithm provide a practical framework for optimizing the management of rifampicin-resistant tuberculosis (RR-TB). This approach effectively balances the need for diagnostic speed with therapeutic accuracy in programmatic settings.
Related
- Real-world evaluation of the FluoroType MTBDR 2.0 assay for detection of rifampicin and isoniazid resistance-conferring mutations in Mycobacterium tuberculosis complex clinical isolates
- Annual trends in Mycobacterium tuberculosis detection and rifampicin resistance at a regional referral hospital in Northern Ghana, 2019–2024
- The Blind Spot of GeneXpert MTB/RIF: Isoniazid‐Resistant, Rifampicin‐Susceptible Tuberculosis Detected on Phenotypic Drug Susceptibility Testing
- Correlation between phenotypic disc diffusion test and PCR molecular test for detection of methicillin resistance in Staphylococcus epidermidis and Staphylococcus hominis.
- An optimized product-enhanced reverse transcriptase assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance
BibTeX
@article{huang2026probelevel,
title = {{Probe-level performance of Xpert MTB/RIF versus phenotypic culture for rifampicin resistance detection and a triage algorithm based on 3,360 clinical specimens in China.}},
author = {Yuliang Huang and Shunda Luo and Jinfeng Lu and Chaoyong He and Diyu Mai and Qiuying Ma and Wanhong Huang and Hanzhen Su and Zhengkang Li and Liang Zhang and Xiaocheng Luo},
journal = {BMC infectious diseases},
year = {2026},
month = jul,
doi = {10.1186/s12879-026-14037-4},
url = {https://europepmc.org/article/MED/42928142},
note = {CC BY},
}
RIS
TY - JOUR
TI - Probe-level performance of Xpert MTB/RIF versus phenotypic culture for rifampicin resistance detection and a triage algorithm based on 3,360 clinical specimens in China.
AU - Yuliang Huang
AU - Shunda Luo
AU - Jinfeng Lu
AU - Chaoyong He
AU - Diyu Mai
AU - Qiuying Ma
AU - Wanhong Huang
AU - Hanzhen Su
AU - Zhengkang Li
AU - Liang Zhang
AU - Xiaocheng Luo
PY - 2026
DA - 2026/07/28
JO - BMC infectious diseases
DO - 10.1186/s12879-026-14037-4
UR - https://europepmc.org/article/MED/42928142
AB - Background The Xpert MTB/RIF (Xpert) assay is a cornerstone for the rapid detection of rifampicin resistance. However, discordant results between Xpert and phenotypic drug susceptibility testing (pDST) present diagnostic challenges, particularly in regions with genetically diverse Mycobacterium tuberculosis populations. This study aimed to evaluate the performance of Xpert at the probe level to resolve such discrepancies and to inform an optimized diagnostic workflow.Methods Using a retrospective cohort of 3,360 clinical specimens from a high-burden setting in China, we compared Xpert results with pDST as the reference standard. We then performed a stratified analysis based on specific probe mutation patterns to determine their predictive value for phenotypic resistance.Results Overall, Xpert demonstrated substantial agreement with pDST (κ = 0.722, 95% CI: 0.685-0.759), exhibiting a sensitivity of 80.4% and a specificity of 95.8%. However, concordance was highly dependent on the specific probe mutation. Mutations in Probe E were strongly predictive of phenotypic resistance (Positive Predictive Value: PPV: 91.4%). In contrast, The mutations detected by Probe ΔCt and Probe A exhibited a low PPV of only 28.0% and 14.3%, respectively. Based on these findings, we propose a diagnostic triage strategy: results indicating Probe E mutations can reliably guide immediate treatment adjustments, whereas isolated ProbeΔCt resistance, or Probe A mutations, warrant confirmatory pDST before initiating second-line regimens.Conclusion The clinical interpretation of Xpert results requires a nuanced understanding of probe-specific mutation patterns. Our probe-stratified analysis and the resulting triage algorithm provide a practical framework for optimizing the management of rifampicin-resistant tuberculosis (RR-TB). This approach effectively balances the need for diagnostic speed with therapeutic accuracy in programmatic settings.
SN - 1471-2334
ER -